Is Allogene Therapeutics Inc (ALLO) overvalued? · rev $22.0K
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
This page asks whether Allogene Therapeutics Inc (ALLO) looks expensive on cached numbers — not a short thesis.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
ALLO currently screens at market cap $258.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ALLO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ALLO stock page for the full model, not this heading.
Not investment advice.